SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES

A randomized, double-blind, phase III clinical trial (Aug 2019–Oct 2021) in Iran compared Xacrel (300 mg, then 600 mg every 24 weeks) to Ocrevus (same regimen) in MS patients. Primary outcome was ARR reduction equivalence at week 48. Secondary outcomes included disability progression, relapse-free patients, MRI lesion changes, and safety assessments. The study adhered to ethical and regulatory standards.